Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Samrat Pharmachem's earnings per share without non-recurring items for the
three
months ended in Mar. 2026 was ₹-6.59.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-10.72.
During the past 12 months, Samrat Pharmachem's average earnings per share (NRI) Growth Rate was -146.60% per year.
During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Samrat Pharmachem's EPS without NRI or its related term are showing as below:
During the past 13 years, Samrat Pharmachem's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 123.70% per year. The lowest was -55.90% per year. And the median was 19.70% per year.
BOM:530125's 3-Year EPS without NRI Growth Rate is not ranked *
in the Chemicals industry.
Industry Median: -1.5 * Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
Samrat Pharmachem's EPS (Diluted) for the
three
months ended in Mar. 2026 was ₹-6.59.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-10.72.
Samrat Pharmachem's EPS (Basic) for the
three
months ended in Mar. 2026 was ₹-6.59.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-10.72.
Samrat Pharmachem (BOM:530125) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Samrat Pharmachem EPS without NRI Related Terms
Samrat Pharmachem EPS without NRI Historical Data
* Premium members only.
The historical data trend for Samrat Pharmachem's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Samrat Pharmachem's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Samrat Pharmachem PE Ratio without NRI vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Samrat Pharmachem's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Samrat Pharmachem's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-10.72
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Samrat Pharmachem (BOM:530125) has a EPS without NRI of ₹-10.72 as of Mar. 2026. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Samrat Pharmachem and its competitors. According to the industry distribution chart, Samrat Pharmachem ranks #999999 out of 1255 companies in the Chemicals industry.
Is Samrat Pharmachem's EPS without NRI too high?
Samrat Pharmachem's current EPS without NRI is ₹-10.72. Based on the distribution chart, Samrat Pharmachem ranks #999999 out of 1255 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Samrat Pharmachem has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Samrat Pharmachem's EPS without NRI compare to DOW?
According to the Chemicals industry distribution chart, Samrat Pharmachem ranks #999999 out of 1255 companies for EPS without NRI. This places Samrat Pharmachem in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Chemicals company?
A good EPS without NRI depends on the Chemicals industry context. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Samrat Pharmachem and its competitors. Samrat Pharmachem's current EPS without NRI is ₹-10.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samrat Pharmachem stock overvalued right now?
Based on GuruFocus' analysis, Samrat Pharmachem (BOM:530125) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹362.28, compared to a current price of ₹237.05 — trading 34.6% below its estimated fair value. The current EPS without NRI is ₹-10.72. Samrat Pharmachem's overall GF Score™ is 70/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Samrat Pharmachem (BOM:530125), the current EPS without NRI is ₹-10.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samrat Pharmachem (BOM:530125) Overvalued in 2026?
Based on GuruFocus' analysis, Samrat Pharmachem stock appears to be undervalued.
The current stock price of ₹237.05 is trading 34.6% below its estimated GF Value™ of ₹362.28.
GuruFocus considers Samrat Pharmachem to be Significantly Undervalued.
Key valuation signals for BOM:530125:
EPS without NRI: ₹-10.72
GF Value™: ₹362.28 vs. price of ₹237.05 (34.6% below fair value)
No single metric tells the full story. See the BOM:530125 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samrat Pharmachem Ltd is a producer of pharmaceutical chemicals. The principal activity of the company is to manufacture Iodine salts and bromine salts. Its product portfolio consists of potassium iodate, potassium iodide, methyl iodide, and copper iodide. Its products are used in various industries like pharmaceuticals and chemicals.
70GF Score
Get the complete analysis for BOM:530125
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530125 has been successfully added to your 
